Liu Cong, Bai Ying, Bai Qingquan, Parra Maria A, Zhao Liangliang, Zou Jiashu, Cao Qian, Liu Haoling, Yang Haiyan
Hepatic and Liver Transplantation Division, Department of Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Department of Hepatobiliary Surgery, Weihai Central Hospital Affiliated to Qingdao University, Weihai, People's Republic of China.
J Hepatocell Carcinoma. 2025 Jul 20;12:1495-1507. doi: 10.2147/JHC.S515730. eCollection 2025.
The postoperative recurrence of hepatocellular carcinoma (HCC), influenced by various factors, including microvascular invasion (MVI), plays a critical role in the long-term prognosis following radical liver resection. This study investigated potential adjuvant treatment strategies for HCC patients who exhibit multiple recurrence factors after radical resection.
A retrospective analysis was conducted on data from 243 patients who underwent radical resection for HCC and exhibited high recurrence factors at the First Affiliated Hospital of Harbin Medical University. Some of these patients received postoperative adjuvant therapy with Huaier granules, lenvatinib, or a combination of both, while others did not receive any postoperative adjuvant therapy.
Survival analysis showed a more favorable prognosis in the adjuvant Huaier granules and lenvatinib groups (all P < 0.05). Furthermore, when compared to monotherapy, the combination therapy group exhibited significantly improved overall survival (OS) (P = 0.001) and disease-free survival (DFS) (P = 0.001). Multivariate Cox regression analysis demonstrated that the addition of Huaier granules to lenvatinib was an independent protective factor associated with improved OS (hazard ratio (HR) = 0.777, 95% confidence interval (CI) = 0.616-0.980, P = 0.033) and DFS (HR = 0.753, 95% CI = 0.615-0.920, P = 0.006).
In this retrospective analysis, the combination of Huaier granules and lenvatinib as postoperative adjuvant therapy was associated with improved long-term prognosis in patients at high risk of HCC recurrence.
肝细胞癌（HCC）术后复发受多种因素影响，包括微血管侵犯（MVI），在根治性肝切除术后的长期预后中起关键作用。本研究调查了根治性切除后出现多种复发因素的HCC患者的潜在辅助治疗策略。
对哈尔滨医科大学附属第一医院243例行HCC根治性切除且具有高复发因素的患者的数据进行回顾性分析。其中一些患者接受了槐耳颗粒、仑伐替尼或两者联合的术后辅助治疗，而其他患者未接受任何术后辅助治疗。
生存分析显示，辅助使用槐耳颗粒和仑伐替尼的组预后更佳（所有P<0.05）。此外，与单一疗法相比，联合治疗组的总生存期（OS）（P = 0.001）和无病生存期（DFS）（P = 0.001）显著改善。多因素Cox回归分析表明，在仑伐替尼基础上加用槐耳颗粒是与改善OS（风险比（HR）= 0.777, 95%置信区间（CI）= 0.616 - 0.980, P = 0.033）和DFS（HR = 0.753, 95% CI = 0.615 - 0.920, P = 0.006）相关的独立保护因素。
在这项回顾性分析中，槐耳颗粒与仑伐替尼联合作为术后辅助治疗与HCC复发高危患者的长期预后改善相关。
